Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
A Single-arm, Open-label, Multicenter Phase III Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-demand Treatment in Patients With Severe Hemophilia A (Adults and Adolescents) .
The indication for this product is to control bleeding in patients with hemophilia A (congenital deficiency of factor VIII).
The primary objective:
Evaluation of the efficacy of recombinant human coagulation factor VIII-Fc fusion protein for injection (FRSW107) as an on-demand treatment in previously treated patients with severe hemophilia A.
Secondary objectives:
Evaluation of the safety and immunogenicity of FRSW107 as an on-demand therapy in previously treated patients with severe hemophilia A.
Evaluate the on-demand treatment's PK profile of FRSW107 in previously treated patients with severe hemophilia A based on population pharmacokinetic (PopPK) methods ; preliminarily investigate the exposure-response (E-R) relationship of FRSW107 on-demand treatment in these patients if data permit.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Faza 3
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Lijia Liu
- Numer telefonu: + 86 1645377793
- E-mail: lijialiu@gensciences.cn
Lokalizacje studiów
-
-
-
Fuyang, Chiny
- Fuyang Hospital, Affiliated to Anhui Medical University
-
Fuzhou, Chiny
- Fujian Medical University Union Hospital
-
Ganzhou, Chiny
- Ganzhou People's Hospital
-
Guangzhou, Chiny
- Nanfang Hospital of Southern Medical University
-
Hefei, Chiny
- Anhui Provincial Hospital
-
Huai'an, Chiny
- Huai'an Second People's Hospital
-
Jinan, Chiny
- Jinan Central Hospital
-
Kunming, Chiny
- The Second Affiliated Hospital of Kunming Medical University
-
Nanning, Chiny
- The First Affiliated Hospital of Guangxi Medical University
-
Nantong, Chiny
- Affiliated Hospital of Nantong University
-
Nanyang, Chiny
- The First Affiliated Hospital of Nanyang Medical College
-
Qinghai, Chiny
- Qinghai Provincial People's Hospital
-
Rizhao, Chiny
- Rizhao People's Hospital
-
Shijiazhuang, Chiny
- The Second Hospital of Hebei Medical University
-
Taiyuan, Chiny
- The Second Hospital of Shanxi Medical University
-
Tangshan, Chiny
- North China University of Science and Technology Affiliated Hospital
-
Wenzhou, Chiny
- Wenzhou People's Hospital
-
Wuhan, Chiny
- Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology.
-
Wuxi, Chiny
- Affiliated Hospital of Jiangnan University
-
Xi'an, Chiny
- Xi'an Central Hospital
-
Yangzhou, Chiny
- Subei People's Hospital of Jiangsu province
-
Zhengzhou, Chiny
- Henan Cancer Hospital
-
Zhengzhou, Chiny
- Zhengzhou People's Hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Chiny
- Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dziecko
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Opis
Inclusive Criteria:
- Males aged 12 or younger to 65 years old.
- Patients clinically diagnosed with severe hemophilia A, i.e., those confirmed through screening or previous medical records: FⅧ Activity < 1%.
- Previous records confirm receipt of any recombinant and/or blood-derived coagulation factor VIII products or cold precipitate products, with a treatment of ≥150 exposure days (EDs ≥150).
- The participants have fully understood and been informed of this study, signed the informed consent form, and voluntarily enrolled in the clinical trial. The trial participants and/or their guardians are capable of cooperating with the hemostatic treatment and have the ability to complete all study procedures.
Exclusion Criteria:
- Known or suspected allergy to the investigational drug or its excipients, including mouse or hamster proteins;
- Hypersensitivity or anaphylaxis after FⅧ or IgG2 injection in the past;
- FⅧ inhibitor positive (≥0.6 BU/mL) during the screening period, or have a history of FⅧ inhibitor positive in the past, or a family history of FⅧ inhibitor positive;
- Von Willebrand factor (vWF) antigen test results were lower than the lower limit of normal value;
- Severe anemia at the screening stage (hemoglobin < 60 g/L);
- Platelet count during screening period < 100×109 /L;
Abnormal liver function:
.Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) >3 times upper limit of normal (ULN); or Serum total bilirubin (TBIL) >1.5x ULN;
Patients with abnormal renal function:
Creatinine clearance (Ccr) <50 ml/min (according to Cockcroft and Gault formula); or Serum creatinine (Cr) >1.5x ULN;
- People with active hepatitis C, that is, hepatitis C virus (HCV) antibody positive and HCV RNA positive; Or anti-treponema pallidum specific antibody (TPHA) positive; Or positive for antibodies against the human immunodeficiency virus (HIV);
- Patients with coagulation dysfunction other than hemophilia A;
- Have a medical condition that may increase the risk of bleeding;
- A history of drug or alcohol abuse;
- Have a known mental disorder that may affect trial compliance;
- Patients who have received transfusions of blood or blood components within 4 weeks prior to screening;
- Participants who had participated in other clinical trials within 1 month before screening;
- Use of any anticoagulant or antiplatelet drugs, off-label maximum dose of non-steroidal anti-inflammatory drugs (NSAID) within 7 days prior to screening; Or patients who need to be treated with anticoagulant or antiplatelet drugs or off-label maximum doses of SAID during clinical trials;
- Severe cardiovascular and cerebrovascular disease or major thromboembolic events, such as stroke, myocardial infarction, unstable angina, congestive heart failure (New York Heart Association [NYHA] grade ≥ III), and severe arrhythmias (including QTc interphase > 480 ms, corrected by Fridericia formula), uncontrolled hypertension (systolic ≥ 160 mmHg or diastolic ≥100 mmHg), deep vein thrombosis, etc.
- Study patients who had used emesezumab within 6 months prior to first administration of the drug;
- Patients who had used monoclonal antibody therapy, Fc fusion protein products (except FRSW107 and FRSW117), PEG products (except FRSW117), or intravenous immunoglobulin infusion within 3 months before the first administration of the investigational drug;
- Study patients who underwent major surgery within 3 months prior to initial drug administration (major surgery is defined in 6.2.3 Perioperative management);
- Study patients who have used FⅧ preparation of any standard half-life (e.g., Bycoch, Coproch, Biinidin, Renjie, NoL, Antaine, etc.) within 3 days or 5 half-lives prior to first administration of the drug (taking the elderly); Patients who have used any other extended half-life preparation FⅧ within 4 days or 5 half-lives prior to first dosing (for the elderly);
- Study patients with fever, severe active bacterial or viral infection, and allergies within 2 weeks before the first administration of the drug;
- Systemic immunomodulators (such as glucocorticoids [> 10 mg/ day equivalent dose of prednisone], alpha-interferon, immunoglobulin, cyclophosphamide, cyclosporin, etc.) used within 14 days prior to the first administration of the study drug or planned during the study period were allowed to be inhaled, nasal spray, or topical corticosteroids;
- Those who had been vaccinated within 4 weeks prior to initial administration of the study drug; Or who plan to be vaccinated during PK blood collection (only for subjects in the PK subgroup);
- Plan to have a child or sperm donation during the entire trial period and within 3 months after the last dose, or do not want to use effective physical contraception (such as condoms, diaphragms, Iuds, etc.);
- Have other serious medical conditions that the researchers said could not benefit from them
- Subjects deemed unsuitable by other investigators.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: On-demand Treatment.
On-demand treatment (recommended range: 20-50 IU/kg)
|
Treatment for 6 months as needed.
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
The haemostatic effective rate
Ramy czasowe: 6 months
|
The haemostatic effect of FRSW107 when used for treatment of bleeds, assessed on a four-point scale for haemostatic response (excellent, good, moderate and none) by counting excellent and good as success and moderate and none as failure.
|
6 months
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of infusions and IU/kg of FRSW107 needed for the treatment of bleeding episodes
Ramy czasowe: 6 months
|
6 months
|
|
|
FVIII activity during on-demand: activity recovery rate
Ramy czasowe: Visit1,Day1
|
FVIII activity recovery rate on Day1's haemostatic therapy.
|
Visit1,Day1
|
|
Hemophilia Joint Health Score (HJHS 2.1) during on-demand treatment
Ramy czasowe: 6 month
|
total score and each subscale score of HJHS 2.1, as well as their changes over time.
|
6 month
|
|
incidence of lack of drug efficacy
Ramy czasowe: 6 months
|
Lack of drug efficacy is defined as: during on-demand treatment, hemostatic efficacy is assessed as "ineffective" or "poor/no response" following two consecutive administrations within 72 hours for the same bleeding episode. incidence of lack of drug efficacy=number of lack of drug efficacy/number of evaluated treatment*100%. |
6 months
|
|
Occurrence of AEs and SAEs
Ramy czasowe: 6 month
|
6 month
|
|
|
Incidence rate of positive FVIII inhibitors
Ramy czasowe: 6 month
|
A positive FⅧ inhibitor is defined as a Bethesda inhibitor titer ≥ 0.6 BU/mL.
Incidence rate of positive FVIII inhibitors=number of positive FⅧ inhibitors participant / total number of trial participants *100%.
|
6 month
|
|
Incidence rate of positive ADA, Incidence rate of positive anti-CHO antibody
Ramy czasowe: 6 month
|
Incidence rate of positive ADA=number of positive ADA participant / total number of trial participants *100% Incidence rate of positive anti-CHO antibody=number of positive anti-CHO antibody participant / total number of trial participants *100%
|
6 month
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Krzesło do nauki: Renchi Yang, PhD, Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- SS-107-III05
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .